Sinovac benefits from Chinese vaccine order
This article was originally published in Scrip
Executive Summary
Sinovac Biotech has received a Yuan87 million ($12.8 million) order from China's ministry of public health for its hepatitis A vaccine Healive. Sinovac will be the sole supplier of the inactivated vaccine under a tender for a national inoculation campaign. This will cover children aged 18 months to 12 years in 32 cities and counties across nine provinces, the Beijing-based company said. Sinovac recently increased its annual production capacity for Healive to 20 million doses, and is also targeting the private market. It also markets other hepatitis and flu vaccines and is working on pandemic flu and Japanese encephalitis vaccines.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.